Eli Lilly Signs Significant Agreement with Seamless Therapeutics to Advance Gene Editing for Hearing Loss

Eli Lilly has entered a 1.12 billion dollar partnership with Seamless Therapeutics to develop hearing loss treatments. The deal focuses on gene-editing technology.

洞察:
Eli Lilly and Company announced on Wednesday it has signed an agreement worth up to $1.12 billion with Seamless Therapeutics to develop and commercialize treatments for hearing loss. This partnership provides Eli Lilly and Company, based in the USUS, with access to a proprietary gene-editing platform from the DEDE biotech firm to address genetic mutations linked to hearing impairment. Under the terms of the agreement, Eli Lilly and Companywill oversee the entire development process, beginning with preclinical testing and extending through to eventual commercialization.
Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake
Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake